Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.
paper
Cited
Public
- Authors
- Drozda, Katarzyna; Müller, Daniel J; Bishop, Jeffrey R
- Year
- 2014
- Journal
- Pharmacotherapy
- PMID
- 24523097
- DOI
- 10.1002/phar.1398
- PMCID
- PMC3939793
Advancements in pharmacogenomics have introduced an increasing number of opportunities to bring personalized medicine into clinical practice. Understanding how and when to use this technology to guide pharmacotherapy used to treat psychiatric and neurological (neuropsychiatric) conditions remains a challenge for many clinicians. Currently, guidelines exist to assist clinicians in the use of existing genetic information for drug selection and/or dosing for the tricyclic antidepressants, carbamazepine, and phenytoin. Additional language in the product labeling suggests that genetic information may also be useful for determining the starting and target doses, as well as drug interaction potential, for a number of other drugs. In this review, we outline the current status of pharmacogenomic testing for neuropsychiatric drugs as it pertains to information contained in drug labeling, consensus guidelines, and test panels, as well as considerations related to obtaining tests for patients.
No figures extracted from this document.
1–20 of 39
Next →
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | 2018 | 29897633 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Tailoring treatments: pharmacogenomics in the management of neurodegenerative diseases. | Roy KK et al. | — | 2026 | → |
| Identification of key genes and pathways in schizophrenia: a bioinformatics analysis based on GWAS and GEO. | Shokrgozar A et al. | — | 2025 | → |
| Untested, unlicensed, unregulated: prescribing and oversight issues in physician-assisted dying/suicide. | Hollins S et al. | — | 2025 | → |
| Severe Multiple Drug Intolerance Syndrome in Fibromyalgia and Irritable Bowel Syndrome. | Alvarez AA et al. | — | 2024 | → |
| Controversies Around COVID-19 Vaccines and Antidepressants: Scope and Perspective in Malaysia. | Chong Guan N et al. | — | 2023 | → |
| Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study. | Scherf-Clavel M et al. | — | 2023 | → |
| Cytochromes P450 and P-Glycoprotein Phenotypic Assessment to Optimize Psychotropic Pharmacotherapy: A Retrospective Analysis of Four Years of Practice in Psychiatry. | Delage C et al. | — | 2022 | → |
| Effects of Pharmacokinetic Gene Variation on Therapeutic Drug Levels and Antidepressant Treatment Response. | Scherf-Clavel M et al. | — | 2022 | → |
| Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. | Zhou J et al. | — | 2021 | → |
| Pharmacogenetic information in Swiss drug labels - a systematic analysis. | Jeiziner C et al. | — | 2021 | → |
| Stroke Genetics: Turning Discoveries into Clinical Applications. | Dichgans M et al. | — | 2021 | → |
| ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder. | Noel JM et al. | — | 2020 | → |
| Clinical utility of pharmacogenetic testing in the treatment of bipolar disorder of Chinese patients. | Huilei X et al. | — | 2020 | → |
| How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing? | Carvalho Henriques B et al. | — | 2020 | → |
| Patients' Perspectives on Psychiatric Pharmacogenetic Testing. | Liko I et al. | — | 2020 | → |
| Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. | Veldic M et al. | — | 2019 | → |
| Effectiveness of a Pharmacogenetic Tool at Improving Treatment Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Clinical Studies. | Vilches S et al. | — | 2019 | → |
| A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. | Han C et al. | — | 2018 | → |
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | Prytkova I et al. | — | 2018 | → |
| Pharmacogenetic evaluation of a DISP1 gene variant in antidepressant treatment of obsessive-compulsive disorder. | Lisoway AJ et al. | — | 2018 | → |
| Pharmacogenetics. | Bishop JR | — | 2018 | → |
| The role of genetics and genomics in clinical psychiatry. | Hoehe MR et al. | — | 2018 | → |
| Association between <i>CYP2D6</i> Genotypes and the Risk of Antidepressant Discontinuation, Dosage Modification and the Occurrence of Maternal Depression during Pregnancy. | Bérard A et al. | — | 2017 | → |
| Case report: Cytochrome P450 implications for comorbid ADHD and OCD pharmacotherapy. | Hogan MK et al. | — | 2017 | → |
| Economic Utility: Combinatorial Pharmacogenomics and Medication Cost Savings for Mental Health Care in a Primary Care Setting. | Brown LC et al. | — | 2017 | → |
| Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. | Pérez V et al. | — | 2017 | → |
| Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report. | Eum S et al. | — | 2017 | → |
| Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come? | Lozupone M et al. | — | 2017 | → |
| Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis. | Espadaler J et al. | — | 2017 | → |
| Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test. | Health Quality Ontario | — | 2017 | → |
| Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder. | Peterson K et al. | — | 2017 | → |
| Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting. | Bousman CA et al. | — | 2017 | → |
| A review of consent practices and perspectives for pharmacogenetic testing. | Haga SB et al. | — | 2016 | → |
| Biomarkers for drug development in early psychosis: Current issues and promising directions. | Goff DC et al. | — | 2016 | → |
| Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. | Kennedy SH et al. | — | 2016 | → |
| Pharmacogenetic Tests in Psychiatry: From Fear to Failure to Hype. | de Leon J | — | 2016 | → |
| Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. | Panza F et al. | — | 2016 | → |
| Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder. | Sánchez-Iglesias S et al. | — | 2016 | → |
| Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. | Winner JG et al. | — | 2015 | → |
| Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. | Bishop JR et al. | — | 2015 | → |
| Genotypes at rs2844682 and rs3909184 have no clinical value in identifying HLA-B*15:02 carriers. | Zhu GD et al. | — | 2015 | → |
| "Getting off the Bus Closer to Your Destination": Patients' Views about Pharmacogenetic Testing. | Trinidad SB et al. | — | 2015 | → |
| Personalized therapies in psychiatry: promises, pitfalls and perspectives. | Domschke K et al. | — | 2015 | → |
| Physicians' opinions following pharmacogenetic testing for psychotropic medication. | Walden LM et al. | — | 2015 | → |
| SNP genotyping using TaqMan technology: the CYP2D6*17 assay conundrum. | Gaedigk A et al. | — | 2015 | → |
| Genetic determinants of selective serotonin reuptake inhibitor related sexual dysfunction. | Stevenson JM et al. | — | 2014 | → |
| Pharmacogenetic information for patients on drug labels. | Haga SB et al. | — | 2014 | → |
| Pharmacogenetic testing in psychiatry: not (quite) ready for primetime. | Howland RH | — | 2014 | → |
| Prediction of treatment outcomes in psychiatry--where do we stand ? | McMahon FJ | — | 2014 | → |